Codexis Appoints David O’Toole As Chief Financial Officer
Codexis, Inc. (NASDAQ: CDXS), a developer of cost-advantaged processes
for the production of biofuels, bio-based chemicals and pharmaceuticals,
today announced the appointment of David O’Toole as Senior Vice
Codexis, Inc. (NASDAQ: CDXS), a developer of cost-advantaged processes for the production of biofuels, bio-based chemicals and pharmaceuticals, today announced the appointment of David O’Toole as Senior Vice President and Chief Financial Officer, effective September 4, 2012. David O’Toole served most recently as Vice President and Chief Financial Officer at Response Genetics, Inc. (NASDAQ: RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer and analytical testing services of clinical trial specimens for the pharmaceutical industry. In this role, David managed the finance and accounting department and was responsible for investor relations and information technologies. During David’s time at Response Genetics, he implemented policies and procedures across all company functions that resulted in significant cost savings and operational efficiencies for the business. David also successfully completed a number of equity financings. From 2008 to 2009, David was Executive Vice President and Chief Financial Officer of Abraxis Bioscience, Inc., a publicly traded global biotechnology company with a market capitalization of approximately $3 billion. As CFO, David managed a department of 40 people and successfully implemented the company’s first Sarbanes Oxley 404 compliance cycle, a robust financial planning and analysis program and a new ERP system. David also helped establish operations and successfully launch commercial activities in Europe and China. Prior to Abraxis, David spent sixteen years with the accounting firm of Deloitte & Touche LLP, including twelve years as a partner, where he provided international business, operational and tax advice to medium and large multinational companies His time with Deloitte also included two years in Paris, France. David’s practice focused on life science and biotechnology companies during his last eight years at Deloitte. He led a large team of cross functional partners and managers providing consulting services to life science companies. These services included Sarbanes Oxley compliance, revenue cycle management, supply chain management, real estate services, ERP implementation and finance, accounting and tax services.